Virtual Library

Start Your Search

Xarles Erik Luepke



Author of

  • +

    P2.12 - Small Cell Lung Cancer/NET (ID 180)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Small Cell Lung Cancer/NET
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.12-13 - Lurbinectedin (L) Combined with Paclitaxel (P) or Irinotecan (I) in Relapsed SCLC. Results from Two Phase Lb Trials (ID 1588)

      10:15 - 18:15  |  Author(s): Xarles Erik Luepke

      • Abstract
      • Slides

      Background

      L is a new agent that exerts antitumor activity through inhibition of trans-activated transcription and modulation of tumor microenvironment. Preclinical evidence of synergism was observed for L in combination with P and I.

      Method

      Activity of combinations with LP and LI in small cell lung cancer (SCLC) was reviewed in two phase Ib trials. Patients were enrolled following a 3+3 dose escalation design. SCLC patients with ECOG performance status (PS) 0-1 and pretreated with at least one platinum-based chemotherapy are presented. Extensive pharmacokinetic (PK) sampling for L and P or I was performed.

      Result

      19 pts were treated: 7 with LP and 12 with LI. Baseline characteristics (LP/LI) were: males, 57%/45%; median age, 55/57 years; ECOG PS score 1, 57%/92%; chemotherapy-free interval (CTFI) >90 days, 43%/67%; median (range) prior lines, 1 (1-3)/2 (1-3); liver metastases, 29%/33%.

      Lurbinectedin-Paclitaxel

      (L: 2.2 mg/m2 – 5 mg FD +

      P: 60-80 mg/m2) *

      (n=7)

      Lurbinectedin-Irinotecan

      (L: 1-2.4 mg/m2 + I: 75 mg/m2) **

      (n=12)

      ORR (CR+PR)

      CR

      PR

      71% (n=5)

      14% (n=1)

      57% (n=4)

      25% (n=3)

      0%

      25% (n=3)

      ORR in CTFI >90d

      67%

      38%

      CB (CR+PR+SD≥4m)

      71%

      67%

      Median DOR

      2.3 m 95% CI (2.0-NR)

      4.6 m 95% CI (3.0-6.8)

      Median PFS

      4.8 m 95% CI (1.8-12.5)

      5.6 m 95% CI (1.4-8.3)

      * Combination with P given for up to 6 cycles, followed by single-agent L 2.2 mg/m2.

      ** One patient received L 3 mg/m2 + I 15 mg/m2.

      CB, clinical benefit; CR, complete response; CTFI, chemotherapy-free interval; d, days; DOR, duration of response; FD, flat dose; I, irinotecan; L, lurbinectedin; m, months; NR, not reached; ORR, overall response rate; P, paclitaxel; PFS, progression-free survival; PR, partial response; SD, stable disease.

      Adverse events (AEs): grade (G) 4 neutropenia LP/LI 43%/27% of patients; no episodes of febrile neutropenia in LI, one (G3) in LP; no G4 anemia or G4 thrombocytopenia in either study. Non-hematological toxicity was mild and mainly consisted of G3 fatigue (18%) and G3 nausea (7%) in LI; no G3/4 toxicities were found in LP. No toxic deaths and no discontinuations were due to AEs. PK: mean clearance of L (12 L/h in combo with P, and 9.5 L/h in combo with I), of P (31.5 L/h) and of I (32.2 L/h) are comparable with reported data (11.2 L/h, 31.4/h and 25 L/h, respectively).

      Conclusion

      LP and LI combinations showed promising activity after first-line therapy in SCLC. This activity seems consistent with that observed in other trials with L given alone or in combination. Both combinations showed acceptable safety profile. So far, no evidence of major PK drug-drug interactions has been observed. Further development of these combinations is warranted.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.